AIHTA - Publications - Search - Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

Grössmann, N. (2020): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Oncology Fact Sheet Nr. 13.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
65Kb

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WF Respiratory system
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:Oncology Fact Sheet Nr. 13
Deposited on:30 Jun 2020 11:51
Last Modified:30 Jun 2020 11:51

Repository Staff Only: item control page